Serial measurements of the Nt-ProBNP during the dry state in patients with systolic heart failure are predictors of the long-term prognosis

Biomarkers

Volumn 19, Issue 4, 2014, Pages 302-313

  Sargento, Luis ^a   Longo, Susana ^a   Lousada, Nuno ^a   Palma Dos Reis, Roberto ^a  

^a Lisbon   (Portugal)

Author keywords

Nt ProBNP; Prognosis; Serial measurement; Systolic heart failure

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ARTICLE; BLOOD LEVEL; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; LABORATORY TEST; MALE; MEASUREMENT; MORTALITY; OUTPATIENT; PERIODIC MEDICAL EXAMINATION; PLASMA; PROGNOSIS; REPEAT PROCEDURE; SERIAL MEASUREMENT; SYSTOLIC HEART FAILURE; AGED; BLOOD; MIDDLE AGED; PATHOLOGY;

AGED; FEMALE; HEART FAILURE, SYSTOLIC; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 84901319165     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.910549     Document Type: Article

References (39)

1. Anand IS, Fisher LD, Chiang YT, et al. (2003). Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan heart failure trial (Val-heft). Circulation 107:1278-83. (Pubitemid 36314411
2. Bettencourt P, Azevedo A, Pimenta J, et al. (2004a). N-Terminalpro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110:2168-74. (Pubitemid 39372496
3. Bettencourt P, Frioes F, Azevedo A, et al. (2004b). Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93:45-8. (Pubitemid 38068508
4. Braunschweig F, Fahrleitner-Pammer A, Mangiavacchi M, et al. (2006). Correlation between serial measurements of N-Terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients wiThchronic heart failure. Eur J Heart Fail 8:797-803. (Pubitemid 44779416
5. Bruins S, Fokkema MR, Romer JW, et al. (2004). High intraindividual variation of B-Type natriuretic peptide (BNP) and amino-Terminal proBNP in patients wiThstable chronic heart failure. Clin Chem 50: 2052-8. (Pubitemid 39425842
6. Cleland JG, Swedberg K, FollaThF, et al. (2003). The Euroheart failure survey programme-A survey on the quality of care among patients wiThheart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 24:442-63. (Pubitemid 36286187
7. Clerico A, Carlo Zucchelli G, Pilo A, et al. (2006). Clinical relevance of biological variation: The lesson of brain natriuretic peptide (BNP) and Nt-ProBNP assay. Clin Chem Lab Med 44:366-78
8. Cowie MR, Fox KF, Wood DA, et al. (2002). Hospitalization of patients wiThheart failure: A population-based study. Eur Heart J 23:877-85. (Pubitemid 34717423
9. Fonarow GC, Peacock WF, Phillips CO, et al. (2007). Admission B-Type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 49:1943-50. (Pubitemid 46694287
10. Fox KF, Cowie MR, Wood DA, et al. (1997). Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 18: 1771-9
11. Franke J, Frankenstein L, Schellberg D, et al. (2011). Is there an additional benefit of serial NT-proBNP measurements in patients wiThstable chronic heart failure receiving individually optimized therapy? Clin Res Cardiol 100:1059-67
12. Frankenstein L, Remppis A, Frankenstein J, et al. (2009). Variability of n-Terminal probrain natriuretic peptide in stable chronic heart failure and its relation to changes in clinical variables. Clin Chem 55: 923-9
13. Gaggin HK, Truong QA, Rehman SU, et al. (2013). Characterization and prediction of natriuretic peptide nonresponse during heart failure management: Results from the ProBNP outpatient tailored chronic heart failure (PROTECT) and the Nt-Pro-Assisted treatment to lessen serial cardiac readmissions and deaTh(BATTLESCARRED) study. Congest Heart Fail 19:135-42
14. Gardner RS, Chong KS, Morton JJ, McDonagh TA. (2007). A change in N-Terminal pro-brain natriuretic peptide is predictive of outcome in patients wiThadvanced heart failure. Eur J Heart Fail 9:266-71. (Pubitemid 46330136
15. Heidenreich PA, Trogdon JG, Khavjou OA, et al. (2011). Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 123: 933-44
16. Kinnunem P, Vuolteenaho O, Ruskoaho H. (1993). Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: Effect of stretching. Endocrinology 132:1961-70. (Pubitemid 23133241
17. Lam CS, Burnett Jr JC, Costello-Boerrigter L, et al. (2007). Alternate circulating pro-B-Type natriuretic peptide and B-Type natriuretic peptide forms in the general population. J Am Coll Cardiol 49: 1193-202. (Pubitemid 46400332
18. Latini R, Masson S, Wong M, et al. (2006). Incremental prognostic value of changes in B-Type natriuretic peptide in heart failure. Am J Med 119:70.e23-70.e30
19. Levy D, Kenchaiah S, Larson MG, et al. (2002). Long-Term trends in the incidence of and survival wiThheart failure. N Engl J Med 347: 1397-402. (Pubitemid 35239711
20. Luers C, Schmidt A, Wachter R, et al. (2010). Serial NT-proBNP measurements for risk stratification of patients wiThdecompensated heart failure. Herz 35:488-95
21. Luthje L, Vollmann D, Drescher T, et al. (2007). Intrathoracic impedance monitoring to detect chronic heart failure deterioration: Relationship to changes in NT-proBNP. Eur J Heart Fail 9:716-22. (Pubitemid 46702828
22. Maisel A, Barnard D, Jaski B, et al. (2013). Primary results of the HABIT Trial (Heart Failure Assessment WiThBNP in the Home). J Am Coll Cardiol 61:1726-35
23. Masson S, Latini R, Anand IS, et al. (2008). Prognostic value of changes in N-Terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997-1003
24. McMurray JJ, Adamopoulos S, Anker SD, et al. (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration wiThthe Heart Failure Association (HFA) of the ESC. Eur Heart J 33:1787-847
25. Miller WL, Hartman KA, Burrit MF, et al. (2007). Serial biomarker measurement in ambulatory patients wiThchronic heart failure: The importance of change over time. Circulation 116:349-57
26. Moertl D, Hammer A, Huelsmann M, et al. (2008). Prognostic value of sequential measurements of amino-Terminal prohormone of B-Type natriuretic peptide in ambulatory heart failure patients. Eur J Heart Fail 10:404-11
27. Mo?llmann H, Weber M, Elsässer A, et al. (2008). Nt-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 72:921-5. (Pubitemid 351879912
28. Nishiyama K, Tsutamoto T, Yamaji M, et al. (2011). Biological variation of brain natriuretic peptide and cardiac events in stable outpatients wiThnonischemic chronic heart failure. Circ J 75:341-7
29. Olsson LG, Swedberg K, Cleland JG, et al. (2007). Prognostic importance of plasma nt-pro bnp in chronic heart failure in patients treated wiTha beta-blocker: Results from the carvedilol or metoprolol European trial (COMET) trial. Eur J Heart Fail 9:795-801. (Pubitemid 47225165
30. Omland JL, Hagve TA. (2009). Natriuretic peptides: Phy iologic and analytic considereations. Heart Fail Clin 5:471-87
31. Pang PS, Komajda M, Gheorghiade M. (2010). The current and future management of acute heart failure syndromes. Eur Heart J 31:784-93
32. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR. (2007a). Long-Term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28:177-82
33. Schou M, Gustafsson F, Nielsen PH, et al. (2007b). Unexplained weekto-week variation in BNP and NTproBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9:68-74. (Pubitemid 46074482
34. Schou M, Gustafsson F, Videbaek L, et al. (2013). Adding serial N-Terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients wiThsystolic heart failure: A multicenter randomized clinical trial (NorthStar monitoring study). Eur J Heart Fail 15:818-27
35. Troughton RW, Frampton CM, Yandle TG, et al. (2000). Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355:1126-30. (Pubitemid 30172933
36. Troughton RW, Richards A M. (2008). Outpatient monitoring and treatment of chronic heart failure guided by amino-Terminal Pro-B-Type natriuretic peptide measurement. Am J Cardiol 101: 72A-5A.
37. Tsuchida K, Tanabe K. (2004). Influence of paroxysmal atrial fibrillation attack on brain natriuretic peptide secretion. J Cardiol 44:1-11. (Pubitemid 40745814
38. Wu AH, Smith A, Wieczorek S, et al. (2003). Biological variation for N-Terminal pro-And B-Type natriuretic peptides and implications for therapeutic monitoring of patients wiThcongestive heart failure. Am J Cardiol 92:628-31. (Pubitemid 37013426
39. Yancy CW, Jessup M, Bozkurt B, et al. (2013). ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128:e240-327